BioWorld

June 18, 2010

OncoMed Has 'Wnt' in its Sails; Bayer Deal Adds $40M Up Front

For a firm that has yet to reach Phase II with a lead program, OncoMed Pharmaceuticals Inc. has managed some pretty impressive feats in the past few years. (BioWorld Today) Read More

Neurocrine in $235M Deal with Boehringer for GPR119 Agonists

Arginetix, Immune Control Merge Two Corridors in Vascular Space

Aquinox Raises $25M for Blood, Immune Disorders Molecule

EULAR Roundup

Stimuvax Hold Lifted in NSCLC; Oncothyreon, EMD Move Ahead

Stock Movers

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...